[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cryptogenic-ischemic-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cryptogenic-ischemic-stroke":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100469065","phase-3-pfo-closure-oral-anticoagulants-or-antiplatelet-therapy-after-pfo-associated-stroke-in-patients-aged-60-to-80-years-100469065",false,"NCT05387954","PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years","Transcatheter Patent Foramen Ovale (PFO) Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Between 60 and 80 Years Old : a Randomised Controlled Trial.","CLOSE-2","Inclusion Criteria:\n\n* Man or woman aged 60 to 80 years.\n* Recent (≤ 6 months) ischemic stroke confirmed by cerebral imaging regardless of symptom duration.\n* Absence of a more probable cause of stroke than PFO after a standardized etiological work-up (see addenda).\n* Presence of a PFO with at least 1 of the 2 following characteristics:\n\n  * PFO with large shunt (\\> 20 microbubbles) appearing in the left atrium during at least one of the 3 cardiac cycles after complete opacification of the right atrium, detected either spontaneously or during provocative manoeuvers, on contrast transthoracic (TTE) or transoesophageal (TOE) echocardiography. The diagnosis of PFO by contrast TEE must be confirmed by contrast TOE showing a right-to-left passage of the contrast material across the PFO.\n  * PFO associated with an ASA on transoesophageal echocardiography: excursion \\>10 mm\n* Affiliation to a French Health Insurance system. Informed consent.\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C 4 years.\n* Contraindication to both experimental treatments (PFO closure, oral anticoagulant therapy) or to the reference treatment (antiplatelet therapy) (see paragraph 20.5).\n* Indication to long-term anticoagulant therapy.\n* mRS \\> 3.\n* Presence of other medical conditions that would lead to inability to complete the study or interfere with the assessment of outcomes.\n* Previous surgical or transcatheter treatment of PFO or ASA. Expected impossible follow-up or poor compliance.\n* PFO associated with an atrial septal defect (ASD) requiring closure (significant shunt with impact on the right cavities, elevation of pulmonary pressures or QP\u002FQS\\>2)\n* Patient unable to understand the informed consent form. Patient under tutorship, curatorship, or legal protection.","ALL","60 Years","80 Years",{"count":21,"type":22},792,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","To assess whether PFO closure plus antiplatelet therapy is superior to antiplatelet therapy alone and whether oral anticoagulant therapy is superior to antiplatelet therapy to prevent stroke recurrence in patients aged 60 to 80 years with a PFO with large shunt (\\> 20 microbubbles) or a PFO associated with an ASA (\\> 10 mm), and an otherwise unexplained ischemic stroke.",[28,29],"Cryptogenic Ischemic Stroke","Patent Foramen Ovale",[31,32,33,34,35,36,37,38],"Ischemic stroke","Cryptogenic stroke","Patent foramen ovale","Atrial septal aneurysm","Transcatheter PFO closure","Oral anticoagulants","Antiplatelet therapy","Randomized clinical tria","RECRUITING","2026-03-23",{"date":42,"type":43},"2026-03-24","ACTUAL",{"date":45,"type":43},"2023-07-07",{"date":47,"type":22},"2031-07-07",{"name":49,"class":50},"Assistance Publique - Hôpitaux de Paris","OTHER",42,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100615862","cardiac-assessment-for-thrombus-detection-in-the-heart-using-advanced-imaging-mri-ct-in-esus-with-left-ventricular-disease-100615862","NCT07298122","Cardiac Assessment for Thrombus Detection in the Heart Using Advanced Imaging (MRI, CT) in ESUS With Left Ventricular Disease","CATCH ME","Inclusion Criteria:\n\n* Age between 18 and 85 years Modified Rankin Scale (mRS) score ≤ 4 Diagnosis of acute ischemic stroke (detected by CT or brain MRI) Diagnosis of ESUS according to standard criteria\n* Stroke detected by CT or MRI that is not lacunar. Lacunar is defined as a subcortical infarction (including pons and mesencephalon) in the distribution of the small penetrating cerebral arteries, with a maximum size ≤ 1.5 cm on CT or ≤ 2.0 cm on diffusion-weighted MRI images (\\\u003C 1.5 cm on T2-weighted MRI images). Excluded: multiple small deep infarcts, lateral bulb infarcts, cerebellar infarcts, patients with clinical lacunar stroke syndrome and no visible infarction on imaging.\n* Absence of extracranial or intracranial atherosclerosis causing ≥ 50% stenosis in the artery supplying the ischemic area. Vascular imaging of the extracranial and intracranial vessels is required using angiography, CT angiography (CTA), MR angiography (MRA), or color Doppler ultrasound, at the discretion of the treating physician and local principal investigator.\n* No major cardioembolic source identified, including permanent or paroxysmal atrial fibrillation (AF), sustained atrial flutter, intracardiac thrombus (\\*as specified above, these patients will be recruited in phase 1 of the study only if an isolated ventricular thrombus is found without other major cardiac causes), mechanical heart valve prosthesis, atrial myxoma or other cardiac tumors, moderate or severe mitral stenosis, recent myocardial infarction (\\\u003C 4 weeks), left ventricular ejection fraction (EF) \\\u003C 30%, valve vegetations or infective endocarditis.\n* No other identified cause of stroke (such as arteritis, dissection, migraine, vasospasm, drug abuse, hypercoagulability, etc.)\n\nPresence of LVD defined by at least one of the following criteria:\n\n* Moderately reduced left ventricular (LV) systolic function, defined as EF 30-49%.\n* LV wall motion abnormalities (LVWMAs), defined as hypokinetic, akinetic, or dyskinetic segments of the left ventricular wall not associated with recent or acute myocardial infarction (within 4 weeks).\n* LV aneurysm\n* Enlarged LV with or without spontaneous contrast\n* Non-compacted LV, with deep trabeculations or spongy LV\n* Cardiomyopathies, such as restrictive cardiomyopathy, hypertrophic cardiomyopathy, or cardiac amyloidosis\n\nPatients capable of signing informed consent (IC) or, in the case of unconscious patients without an authorized legal representative, recruited in a \"Deferred\" mode\n\nExclusion Criteria:\n\n* Major cardioembolic sources, as specified in the ESUS criteria Patients with a thrombophilic state secondary to active cancer, defined as \"diagnosis of solid or hematologic malignant tumor within 6 months of stroke, ongoing oncological treatment, or hematologic cancer not in remission.\" Patients with ipsilateral carotid plaques to the ischemic stroke considered at high risk: thrombus on the wall, floating thrombus, ulcerated plaque.\n\nPatients under 60 years of age with a high-risk patent foramen ovale (PFO) and stroke classified as \"probable\" PFO-associated stroke according to the PASCAL classification.\n\nPregnancy or puerperium. Contraindication to MRI and CT with contrast agents","18 Years",{"count":61,"type":22},125,"OBSERVATIONAL","The CATCH ME study is a prospective, multicenter, observational, no-profit study aimed at improving embolic risk stratification in patients with embolic stroke of undetermined source (ESUS), particularly in those with left ventricular disease (LVD). LVD is defined by a mildly to moderately reduced ejection fraction (30-49%), left ventricular wall motion abnormalities (hypo\u002Fakinesia), ventricular dilation, cardiomyopathies, and other related conditions. In these patients, the intermittent formation of intracardiac thrombi within the ventricle, often undetectable by standard diagnostic evaluation such as transthoracic echocardiography (TTE) alone, may serve as an unrecognized embolic source. However, in clinical practice, such patients are frequently discharged on antiplatelet therapy alone, without adequate thromboembolic risk stratification, thus leaving them at a high risk of ischemic recurrence. This study aims to assess the additional diagnostic value of advanced cardiac imaging - Cardiac Magnetic Resonance Imaging (CMRI) and\u002For Cardiac Computed Tomography (CCT) - in detecting intracardiac thrombi not identified by TTE in patients with ESUS and LVD.",[28],"2025-12-11",{"date":67,"type":43},"2025-12-23",{"date":69,"type":43},"2025-09-15",{"date":71,"type":22},"2028-12-31",{"name":73,"class":50},"Niguarda Hospital",1]